Background: Morbidity and mortality associated with non-valvular atrial fibrillation (NVAF)
imposes a substantial economic burden on the UK healthcare system. Objectives: An …

Background To undertake an economic evaluation of rivaroxaban relative to the standard of
care for stroke prevention in patients with non-valvular atrial fibrillation (AF) in Greece …

Objective The objective was to assess the real-world cost-effectiveness of rivaroxaban,
versus vitamin K antagonists (VKAs), for stroke prevention in patients with atrial fibrillation …

Objectives To evaluate the cost-effectiveness of the once daily oral anticoagulant
rivaroxaban for prevention of stroke and systemic embolism in non-valvular atrial fibrillation …

Objective: The aim of this study was to evaluate, from the Spanish National Health System
perspective, the cost-effectiveness of rivaroxaban (20 mg/day) versus use of acenocoumarol …

Objectives To assess the cost-effectiveness of apixaban versus rivaroxaban in the
prevention of stroke in patients with non-valvular atrial fibrillation (NVAF) in Spain. Methods …

Aims A Markov model was adapted to assess the real-world cost-effectiveness of
rivaroxaban, dabigatran and apixaban. Each of these non-vitamin K antagonist oral …

Background Warfarin, an inexpensive drug that has been available for over half a century,
has been the mainstay of anticoagulant therapy for stroke prevention in patients with atrial …

Objective This study aimed to estimate the cost effectiveness of non-vitamin K oral
anticoagulants (NOACs) compared with warfarin for stroke prevention in patients with non …

Objectives To evaluate the cost-effectiveness of the novel anticoagulant rivaroxaban versus
the current standard of care, warfarin, for stroke prevention in nonvalvular atrial fibrillation …